• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.

作者信息

Van de Werf F, Jang I K, Collen D

出版信息

J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.

PMID:2434801
Abstract

The dose-response of an intravenous i.v. infusion for 30 min of recombinant human single-chain urokinase-type plasminogen activator (rscu-PA) was investigated in dogs with 1-h-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil, and thrombolysis was monitored by repeated coronary angiography. Intravenous infusion of rscu-PA at a rate of 2 micrograms/kg/min did not induce lysis within 30 min (n = 4). Infusion at a rate of 4 micrograms/kg/min in 7 dogs produced complete lysis in 2 (within 25 and 27 min), partial lysis in 2 (within 18 and 25 min), and no lysis in 3. Infusion at 8 micrograms/kg/min in four dogs caused complete lysis in three dogs within 18 +/- 3 min (mean +/- SD) and partial lysis in the fourth animal. Infusion at 20 micrograms/kg/min in four dogs induced complete lysis within 14 +/- 3 min. A linear correlation was observed between the infusion rate and the plateau level of rscu-PA in blood. At the highest infusion rate (20 micrograms/kg/min), the concentration of rscu-PA in blood was 2.5 +/- 0.45 microgram/ml, but this was not associated with systemic fibrinolytic activation because the alpha 2-antiplasmin and fibrinogen levels remained essentially unchanged. It is concluded that i.v. infusion of recombinant single-chain urokinase-type plasminogen activator (rscu-PA) at a sufficiently high rate (greater than or equal to 8 micrograms/kg/min) produces coronary thrombolysis without systemic fibrinolysis in dogs.

摘要

相似文献

1
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
2
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.重组单链尿激酶型纤溶酶原激活剂(沙芦普酶)静脉推注或持续输注用于溶栓的比较。犬冠状动脉和股静脉联合血栓形成模型。
Blood. 1990 Oct 15;76(8):1558-63.
3
Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Arzneimittelforschung. 1988 Jan;38(1):138-42.
4
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thromb Res. 1988 Jul 1;51(1):63-74. doi: 10.1016/0049-3848(88)90283-6.
5
Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Thromb Res. 2005;116(6):519-24. doi: 10.1016/j.thromres.2005.02.009. Epub 2005 Mar 17.
6
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.重组人组织型纤溶酶原激活剂与人类单链尿激酶型纤溶酶原激活剂的协同组合。对严重狭窄犬冠状动脉血栓形成模型中溶栓及再闭塞的影响。
Circulation. 1989 Feb;79(2):393-9. doi: 10.1161/01.cir.79.2.393.
7
Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.α2-抗纤溶酶在人血浆中与单链尿激酶型纤溶酶原激活剂进行纤维蛋白特异性凝块溶解中的作用。
Thromb Haemost. 1991 Apr 8;65(4):394-8.
8
Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.在犬冠状动脉血栓形成模型中,将依前列醇类似物他前列烯与重组单链尿激酶型纤溶酶原激活剂联合使用实现额外的心肌挽救。
Arzneimittelforschung. 1989 Apr;39(4):534-8.
9
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.重组单链尿激酶型纤溶酶原激活剂与交联纤维蛋白特异性单克隆抗体缀合物在狒狒静脉血栓形成模型中的溶栓及药代动力学特性
Circulation. 1990 Nov;82(5):1744-53. doi: 10.1161/01.cir.82.5.1744.
10
Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
Jpn Circ J. 1988 Jan;52(1):72-8. doi: 10.1253/jcj.52.72.

引用本文的文献

1
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.重组人微栓酶在犬冠状动脉铜线圈致血栓模型中的溶栓疗效。
J Thromb Thrombolysis. 2010 Jul;30(1):46-54. doi: 10.1007/s11239-009-0400-9.
2
Saruplase in Myocardial Infarction.沙芦普酶治疗心肌梗死
J Thromb Thrombolysis. 1995;2(3):195-204. doi: 10.1007/BF01062710.
3
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.
沙芦普酶与尿激酶治疗急性心肌梗死疗效及安全性的双盲多中心比较:SUTAMI研究组报告
J Thromb Thrombolysis. 1995;2(2):117-124. doi: 10.1007/BF01064379.